SABS
SAB Biotherapeutics Inc (SABS)
Healthcare • NASDAQ • $4.11+0.49%
- Symbol
- SABS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.11
- Daily Change
- +0.49%
- Market Cap
- $288.83M
- Trailing P/E
- N/A
- Forward P/E
- -12.45
- 52W High
- $6.60
- 52W Low
- $1.60
- Analyst Target
- $9.50
- Dividend Yield
- N/A
- Beta
- 0.56
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Company websiteResearch SABS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.